Search - tctmd.com

Displaying 1 - 20 of 269

Sort: Relevancy | Date

Revascularization Decisions in the Elderly Require a Holistic Approach: AHA

News Daily News

Revascularization Decisions in the Elderly Require a Holistic Approach: AHA

November 24, 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

News Conference News AHA 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

November 13, 2025

Lower Mortality With Complete Revascularization in Acute MI Patients With MVD

News Conference News AHA 2025

Lower Mortality With Complete Revascularization in Acute MI Patients With MVD

Michael O'Riordan

November 12, 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

November 03, 2025

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

News Conference News ESC 2025

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

Michael O'Riordan

August 31, 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

News Conference News ESC 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Michael O'Riordan

August 30, 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

News Conference News EuroPCR 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

May 30, 2025

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

DCB Outdo Noncompliant Balloons in Simple Bifurcation Side Branches: DCB-BIF

News Conference News TCT 2024

DCB Outdo Noncompliant Balloons in Simple Bifurcation Side Branches: DCB-BIF

October 28, 2024

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

News Daily News

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

Michael O'Riordan

September 20, 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

News Conference News ESC 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

Michael O'Riordan

September 17, 2024

REC-CAGEFREE I: DCB Fails to Match Up to DES for De Novo CAD

News Conference News ESC 2024

REC-CAGEFREE I: DCB Fails to Match Up to DES for De Novo CAD

September 09, 2024

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

News Daily News

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Michael O'Riordan

July 01, 2024

Coronary Access More Challenging With Self-Expanding Valves: SCAAR/SWENTRY

News Conference News EuroPCR 2024

Coronary Access More Challenging With Self-Expanding Valves: SCAAR/SWENTRY

Michael O'Riordan

May 17, 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

News Conference News EuroPCR 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Yael L. Maxwell

May 15, 2024

Obstructive CAD Can Be Left Alone Before TAVI, Observational Data Suggest

News Daily News

Obstructive CAD Can Be Left Alone Before TAVI, Observational Data Suggest

Michael O'Riordan

January 30, 2024

Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial

News Daily News

Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial

Michael O'Riordan

December 27, 2023

Top Coronary Artery Disease News of 2023

News Daily News

Top Coronary Artery Disease News of 2023

Michael O'Riordan

December 22, 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

News Conference News TCT 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

October 25, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.